Patents by Inventor Todd VERDOORN

Todd VERDOORN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosage forms of tissue kallikrein 1
    Patent number: 12329805
    Abstract: Provided are dosage forms of one or more tissue kallikrein-1 (KLK1) polypeptides which have a total KLK1 polypeptide dosage of about 0.1 ?g/kg to about 10.0 ?g/kg, including subcutaneous and intravenous dosage forms. Also provided are related devices and methods of use thereof, for example, for treating ischemic and hemorrhagic conditions.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: June 17, 2025
    Assignee: DiaMedica Inc.
    Inventors: Rick Pauls, Todd Verdoorn
  • DOSAGE FORMS OF TISSUE KALLIKREIN 1
    Publication number: 20240238389
    Abstract: Provided are dosage forms of one or more tissue kallikrein-1 (KLK1) polypeptides which have a total KLK1 polypeptide dosage of about 0.1 ?g/kg to about 10.0 ?g/kg, including subcutaneous and intravenous dosage forms. Also provided are related devices and methods of use thereof, for example, for treating ischemic and hemorrhagic conditions.
    Type: Application
    Filed: November 3, 2023
    Publication date: July 18, 2024
    Inventors: Rick PAULS, Todd VERDOORN
  • ULINASTATIN POLYPEPTIDES
    Publication number: 20240002472
    Abstract: Provided are ulinastatin glycoforms, ulinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing ulinastatin polypeptides and treating diseases.
    Type: Application
    Filed: June 21, 2023
    Publication date: January 4, 2024
    Inventors: Rick PAULS, Todd VERDOORN, Karl Frank JOHNSON, Gregory Thomas BLECK
  • Dosage forms of tissue kallikrein 1
    Patent number: 11857608
    Abstract: Provided are dosage forms of one or more tissue kallikrein-1 (KLK1) polypeptides which have a total KLK1 polypeptide dosage of about 0.1 ?g/kg to about 10.0 ?g/kg, including subcutaneous and intravenous dosage forms. Also provided are related devices and methods of use thereof, for example, for treating ischemic and hemorrhagic conditions.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: January 2, 2024
    Assignee: DiaMedica Inc.
    Inventors: Rick Pauls, Todd Verdoorn
  • Ulinastatin polypeptides
    Patent number: 11725043
    Abstract: Provided are ulinastatin glycoforms, ulinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing ulinastatin polypeptides and treating diseases.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: August 15, 2023
    Assignee: DiaMedica USA Inc.
    Inventors: Rick Pauls, Todd Verdoorn, Karl Frank Johnson, Gregory Thomas Bleck
  • ULINASTATIN POLYPEPTIDES
    Publication number: 20210277090
    Abstract: Provided are ulinastatin glycoforms, ulinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing ulinastatin polypeptides and treating diseases.
    Type: Application
    Filed: March 5, 2021
    Publication date: September 9, 2021
    Inventors: Rick PAULS, Todd VERDOORN, Karl Frank JOHNSON, Gregory Thomas BLECK
  • DOSAGE FORMS OF TISSUE KALLIKREIN 1
    Publication number: 20210138045
    Abstract: Provided are dosage forms of one or more tissue kallikrein-1 (KLK1) polypeptides which have a total KLK1 polypeptide dosage of about 0.1 ?g/kg to about 10.0 ?g/kg, including subcutaneous and intravenous dosage forms. Also provided are related devices and methods of use thereof, for example, for treating ischemic and hemorrhagic conditions.
    Type: Application
    Filed: March 9, 2018
    Publication date: May 13, 2021
    Inventors: Rick PAULS, Todd VERDOORN